MANGOCEUTICALS, INC.
For the period ended Dec 31, 2025. Filed Apr 1, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Apr 1, 2026
MGRX$0.19-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Operations
| For The Year | For The Year | |
|---|---|---|
| Ended | Ended | |
| December 31, 2025 | December 31, 2024 | |
| Revenues | ||
| Revenues | $456,021 | $615,873 |
| Cost of revenues | 54,422 | 93,296 |
| Cost of revenues - related party | 151,213 | 142,613 |
| Gross profit | 250,386 | 379,964 |
| Operating expenses | ||
| General and administrative expenses | 3,756,373 | 3,000,571 |
| Salary and benefits | 1,348,051 | 1,063,781 |
| Advertising and marketing | 822,860 | 1,478,663 |
| Investor relations | 1,561,206 | 453,749 |
| Stock based compensation | 10,794,245 | 2,355,193 |
| Total operating expenses | 18,282,735 | 8,351,957 |
| Loss from operations | (18,032,349) | (7,971,993) |
| Other (income) expense | ||
| Interest expense | 103,513 | 13,700 |
| Amortization of intangible assets | 1,122,639 | 721,533 |
| Impairment of license agreement | 1,239,942 | |
| Loss from settlement | 125,624 | - |
| Loss from debt extinguishment - related parties | 19,388 | - |
| Total other (income) expense | 2,611,106 | 735,233 |
| Loss before income taxes | (20,643,455) | (8,707,226) |
| Income taxes | - | - |
| Net loss | (20,643,455) | (8,707,226) |
| Net loss attributed to non-controlling interest | (461) | (1,081) |
| Net loss attributed to Mangoceuticals, Inc. | (20,642,994) | (8,706,145) |
| Basic and diluted loss per share | ||
| Basic and diluted loss per share | $(2.17) | $(4.80) |
| Weighted average number of shares outstanding | ||
| Basic and diluted | 10,071,609 | 1,978,966 |
| Basic and diluted loss per share calculation | ||
| Preferred stock dividend requirements | 1,176,000 | 802,109 |
| Net loss attributed to Mangoceuticals, Inc. common stockholders | $(21,818,994) | $(9,508,254) |
Mangoceuticals, Inc. and Subsidiaries
Consolidated Statements of Comprehensive Loss
| For The Year | For The Year | |
|---|---|---|
| Ended | Ended | |
| December 31, 2025 | December 31, 2024 | |
| Net loss | $(20,643,455) | $(8,707,226) |
| Other comprehensive income (loss) | ||
| Foreign currency translation adjustments | (2,760) | (9,845) |
| Comprehensive loss | (20,646,215) | (8,717,071) |
| Less comprehensive loss attributed to non-controlling interest | (1,542) | (1,081) |
| Comprehensive loss attributable to Mangoceuticals, Inc. stockholders | $(20,644,673) | $(8,715,990) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.